Prizloncabtagene Autoleucel (C-CAR039): A Comprehensive Analysis of a Next-Generation Bispecific CAR-T Therapy for B-Cell Malignancies

Executive Summary

Prizloncabtagene autoleucel, an investigational autologous Chimeric Antigen Receptor (CAR) T-cell therapy, represents a significant advancement in the treatment of relapsed or refractory (r/r) B-cell malignancies. Developed under the designation C-CAR039 and now advanced globally as JNJ-90014496 by Johnson & Johnson in partnership with AbelZeta Pharma, this therapy is engineered with a novel bispecific construct targeting both the CD19 and CD20 antigens. This dual-targeting mechanism is designed to overcome a primary failure mode of existing single-target anti-CD19 CAR-T therapies: antigen escape. The CAR construct further incorporates a 4-1BB costimulatory domain, which promotes long-term T-cell persistence and the formation of a durable immune memory response.

Clinical data from a comprehensive development program, including long-term follow-up from studies in China and initial results from a global Phase 1b trial, have demonstrated a remarkably consistent and compelling therapeutic profile. Across multiple cohorts of heavily pre-treated patients with B-cell Non-Hodgkin's Lymphoma (B-NHL), prizloncabtagene autoleucel has achieved exceptionally high overall response rates (ORR) of over 90% and complete response (CR) rates exceeding 85%. More critically, these responses have proven to be deep and durable. With a median follow-up extending beyond 45 months in the pivotal cohort, the median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) have not been reached. The estimated 48-month PFS and OS rates of 52.5% and 65.4%, respectively, in this difficult-to-treat population suggest the potential for curative outcomes in a substantial subset of patients.

Equally significant is the therapy's highly favorable and manageable safety profile. While low-grade Cytokine Release Syndrome (CRS) is common, the incidence of severe (Grade ≥3) CRS is exceptionally low (2.1%), and severe (Grade ≥3) Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) has been rare or absent in most cohorts. This safety profile contrasts favorably with approved CAR-T therapies and suggests the potential for administration in less intensive settings, including outpatient care, which could significantly broaden patient access.

Supported by multiple expedited regulatory designations from the U.S. Food and Drug Administration (FDA)—including Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations—and backed by a major global pharmaceutical partner, prizloncabtagene autoleucel is strongly positioned. The convergence of its superior molecular design, robust and durable clinical efficacy, and favorable safety profile provides a compelling, evidence-based argument for its potential to emerge as a best-in-class therapy, capable of setting a new standard of care for patients with relapsed or refractory B-cell malignancies.

Introduction to Prizloncabtagene Autoleucel

Prizloncabtagene autoleucel is an investigational, personalized cell therapy at the forefront of immuno-oncology, engineered to treat B-cell cancers. As a high-value asset in a competitive therapeutic space, it has been assigned multiple identifiers throughout its development, which are crucial for tracking its clinical and corporate history.

Drug Identification and Developmental Lineage

The therapy is known by several names corresponding to its stage of development and the entities overseeing its progression. Its non-proprietary, or generic, name is Prizloncabtagene autoleucel, often shortened to prizlon-cel.[1] In scientific literature and clinical trial registries, it is most commonly referred to by its development code,

C-CAR039.[4] The therapy is cataloged in the DrugBank database under the accession number

DB18623.[4] Following a major strategic partnership, Johnson & Johnson is advancing the asset globally under the designation

JNJ-90014496, also referred to as JNJ-4496.[7]

The developmental pathway of prizloncabtagene autoleucel is a testament to its perceived value and therapeutic promise. The therapy was originated by Cellular Biomedicine Group Inc. (CBMG), a biopharmaceutical company that conducted the initial investigator-initiated trials in China.[9] CBMG later became

AbelZeta Pharma, Inc., which continued to advance the clinical program and report increasingly mature and compelling long-term data.[2] The strength of these results culminated in a landmark worldwide collaboration and licensing agreement in 2023 with

Janssen Biotech, Inc., a Johnson & Johnson company.[8] This partnership has transitioned the therapy from a regionally developed asset into a global priority, with Johnson & Johnson now leading its clinical development and commercialization strategy outside of Greater China.[7] The corporate evolution and the eventual engagement of a global pharmaceutical leader like Johnson & Johnson serve as a powerful external validation of the asset's scientific rationale and clinical performance. Such a partnership provides not only significant financial backing but also the global manufacturing, regulatory, and commercial infrastructure required to challenge established therapies and achieve a worldwide market presence.

Therapeutic Classification: An Autologous, Second-Generation Bispecific CAR-T Therapy

Prizloncabtagene autoleucel is classified as a biotech therapeutic, specifically falling under the modality of autologous cell transplant therapies.[4] The term "autologous" signifies that the treatment is created on a per-patient basis, originating from the individual's own T-cells. These T-cells are harvested from the patient's blood via a process called leukapheresis, genetically engineered ex vivo to express the CAR, expanded to a therapeutic dose, and then infused back into the same patient.[1]

The core of the therapy is its engineered Chimeric Antigen Receptor (CAR). Prizloncabtagene autoleucel is defined as a second-generation, bispecific CAR T-cell therapy.[1]

• Second-Generation: This refers to the intracellular architecture of the CAR construct. Following the extracellular antigen-binding domain, the CAR contains a primary T-cell activation domain (CD3-zeta), which provides "Signal 1" for T-cell activation, and a single costimulatory domain, which provides "Signal 2" to enhance the potency and persistence of the response.[20] In the case of prizloncabtagene autoleucel, this is the 4-1BB domain.
• Bispecific: This denotes the therapy's advanced antigen recognition capability. Unlike first-generation approved CAR-T therapies that are monospecific (targeting only one antigen), prizloncabtagene autoleucel is designed to simultaneously recognize two distinct B-cell surface antigens: CD19 and CD20.[4] This dual-targeting approach is the central innovation intended to produce a more comprehensive and durable anti-tumor effect.

Scientific Rationale and Advanced Mechanism of Action

The molecular design of prizloncabtagene autoleucel is a sophisticated and intentional effort to address the known limitations of earlier CAR-T therapies. Its mechanism of action is rooted in a synergistic combination of dual-antigen targeting to prevent tumor escape and an optimized costimulatory signal to ensure long-term therapeutic activity.

The Dual-Antigen Targeting Strategy: A Paradigm Shift Beyond CD19 Monotargeting

The foundational innovation of prizloncabtagene autoleucel is its bispecific CAR, which possesses an optimized antigen-binding domain capable of concurrently recognizing and binding to both CD19 and CD20 antigens.[1] CD19 has been the validated and successful target for the first wave of FDA-approved CAR-T therapies for B-cell malignancies.[22] However, clinical experience has shown that under the selective pressure of CD19-directed therapy, cancer cells can evolve to reduce or completely lose CD19 expression on their surface, rendering them invisible to the CAR-T cells and leading to relapse.[24]

CD20 is another protein that is broadly and highly expressed on the surface of both normal and malignant B-cells. By engineering a single CAR construct that can engage both targets, prizloncabtagene autoleucel creates a redundant, dual-lock system for tumor recognition. This design allows the therapy to effectively kill tumor cells that express CD19 alone, CD20 alone, or both antigens simultaneously, as demonstrated in preclinical in vitro and in vivo models.[1]

Mitigating Antigen Escape: The Core Therapeutic Hypothesis

The central therapeutic hypothesis behind the bispecific design is the mitigation of antigen escape, which remains a significant challenge and a primary mechanism of resistance to single-target anti-CD19 CAR-T therapies.[17] When a patient relapses with CD19-negative disease, the initial CAR-T therapy is no longer effective. The dual-targeting strategy of prizloncabtagene autoleucel is designed to preempt this escape route. If a subset of lymphoma cells downregulates or loses CD19, the CAR-T cells can still recognize and eliminate them via the CD20 antigen. This comprehensive targeting is intended to achieve a deeper and more complete depletion of the entire B-cell malignant population, thereby reducing the risk of relapse and leading to more durable remissions.[26] This approach addresses tumor heterogeneity from the outset and is a proactive strategy to enhance the durability of the clinical response.[26]

The 4-1BB Costimulatory Domain: Engineering for Enhanced Persistence and Durable Efficacy

The second critical design element of prizloncabtagene autoleucel is the incorporation of the 4-1BB (also known as CD137) costimulatory domain into its intracellular signaling machinery.[1] When the CAR binds to its target antigen(s), it triggers an initial activation signal ("Signal 1") through its CD3-zeta domain. However, this signal alone is insufficient for a robust and sustained anti-tumor response. A costimulatory signal ("Signal 2") is required to promote T-cell proliferation, survival (persistence), and the development of long-lived memory T-cells capable of providing ongoing immunosurveillance.[20]

The choice of costimulatory domain profoundly influences the behavior and clinical profile of the CAR-T product. The two most common domains used in approved therapies are CD28 and 4-1BB. While CD28 signaling tends to induce rapid and potent T-cell expansion and immediate effector function, it is also associated with a greater risk of T-cell exhaustion and shorter-term persistence.[20] In contrast, 4-1BB signaling typically promotes a more gradual but sustained T-cell expansion, leading to the preferential development of central memory T-cells.[20] This memory phenotype is crucial for long-term persistence of the CAR-T cells in the patient's body. Clinical and preclinical data suggest that 4-1BB-containing CARs are associated with improved persistence, longer duration of response, and a potentially lower risk of severe neurotoxicity compared to their CD28-based counterparts.[30]

The combination of these two distinct engineering strategies—dual-antigen targeting and 4-1BB costimulation—is highly synergistic. The bispecific nature of the CAR addresses the breadth of the anti-tumor attack, ensuring that the therapy can target a heterogeneous tumor population and preempt relapses driven by the loss of a single antigen. The 4-1BB costimulatory domain, in turn, addresses the duration of the attack. It engineers the CAR-T cells for long-term survival and function, creating a persistent cellular therapy that can patrol the body for months or even years, ready to eliminate any residual or re-emerging cancer cells. A persistent CAR-T cell population is more likely to be present to eradicate rare antigen-loss variants that might emerge over time, while the broad targeting mechanism ensures these persistent cells remain effective even as the tumor's antigen profile evolves. This powerful synergy between breadth and duration is the likely molecular basis for the exceptionally deep and durable clinical responses observed with prizloncabtagene autoleucel.

Analysis of the Clinical Development Program

The clinical development of prizloncabtagene autoleucel has been systematic and robust, progressing from early-phase investigator-initiated trials in China to a global, sponsor-led program. The data generated have been consistently positive, building a strong foundation of evidence for its efficacy and safety.

Overview of Key Investigator-Initiated and Sponsor-Led Trials

The initial clinical evaluation of C-CAR039 was conducted through a series of investigator-initiated trials (IITs) across multiple sites in China. These studies, including those registered under identifiers NCT04317885, NCT04655677, NCT04696432, and NCT04693676, were designed as open-label, dose-escalation and expansion trials to establish the therapy's safety, tolerability, and preliminary efficacy.[3] These foundational studies enrolled a cohort of 48 patients with r/r B-NHL, which has provided the basis for the long-term follow-up data presented at major international oncology conferences.[24]

Building on the strength of these results, the program has expanded globally under the stewardship of Johnson & Johnson. The therapy, now designated JNJ-90014496, is being evaluated in a global Phase 1b study to confirm its safety and efficacy in a broader patient population and to establish the recommended Phase 2 dose (RP2D) for future pivotal trials.[7]

Trial Identifier	Phase	Status (as per latest available data)	Conditions Studied	Key Objectives
NCT04317885	Phase 1	Completed	B-Cell Non-Hodgkin's Lymphoma	Evaluate safety and efficacy of C-CAR039 3
NCT04655677	Phase 1	Active, not recruiting	B-Cell Non-Hodgkin's Lymphoma	Evaluate safety and efficacy of C-CAR039 3
NCT04696432	Phase 1	Completed	B-Cell Non-Hodgkin's Lymphoma	Evaluate safety and preliminary efficacy of C-CAR039 3
NCT04693676	Phase 1	Withdrawn	B-Cell Non-Hodgkin's Lymphoma	Evaluate safety and preliminary efficacy of C-CAR039 3
JNJ-90014496	Phase 1b	Ongoing	Relapsed/Refractory Large B-Cell Lymphoma	Determine RP2D; assess safety, efficacy, and pharmacokinetics 7

Profile of the Target Patient Population: Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

The clinical trials for prizloncabtagene autoleucel have focused on adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (B-NHL), a population with significant unmet medical need.[5] The eligibility criteria allowed for the enrollment of patients with several aggressive and indolent subtypes of B-NHL, including:

• Diffuse Large B-cell Lymphoma (DLBCL), including DLBCL not otherwise specified (NOS), transformed Follicular Lymphoma (tFL), and Primary Mediastinal B-cell Lymphoma (PMBCL).[6]
• Follicular Lymphoma (FL).[6]
• Mantle Cell Lymphoma (MCL).[6]

The patient population enrolled represents a particularly challenging-to-treat group. In the 48-patient cohort from the China studies, the median age was 55 years, and a significant majority (75%) had advanced Ann Arbor Stage III/IV disease.[24] These patients were heavily pre-treated, having received a median of

three prior lines of therapy (range, 1-7).[18] All patients had previously received anti-CD20 monoclonal antibody therapy (e.g., rituximab) and alkylating agents, and many were refractory to their last line of treatment.[24] This context of extensive prior treatment and refractory disease is critical for interpreting the clinical outcomes, as it underscores the high efficacy of prizloncabtagene autoleucel in a population with limited or no other viable therapeutic options.

Dosing, Lymphodepletion, and Administration Protocol

The administration of prizloncabtagene autoleucel follows a standard protocol for autologous CAR-T cell therapies. Prior to the infusion of the CAR-T cells, patients undergo a lymphodepleting chemotherapy regimen. This typically consists of three days of intravenous cyclophosphamide (300 mg/m$^2$/day) and fludarabine (30 mg/m$^2$/day).[1] This conditioning chemotherapy temporarily reduces the number of endogenous lymphocytes in the patient, which serves two main purposes: it reduces competition for essential cytokines and creates a more favorable "space" for the infused CAR-T cells to engraft, expand, and persist.[40]

Following lymphodepletion, prizloncabtagene autoleucel is administered as a single intravenous infusion.[1] In the dose-escalation phases of the initial trials, dose levels ranged from

1.0 x 10$^6$ to 5.0 x 10$^6$ CAR-T cells per kg of body weight.[18] In the global JNJ-90014496 study, the recommended Phase 2 dose (RP2D) was established as a flat dose of

75 million total CAR-positive T-cells.[8]

Manufacturing and Logistics: The Vein-to-Vein Journey

The manufacturing of prizloncabtagene autoleucel is a critical component of the therapy and has been optimized for efficiency and consistency. The process begins with leukapheresis to collect peripheral blood mononuclear cells from the patient. These cells are then transported to a centralized Good Manufacturing Practice (GMP) facility.

The CAR-T cells are manufactured using a serum-free, fully closed, and semi-automated system, specifically the Miltenyi Biotec CliniMACS Prodigy® System.[1] This platform integrates cell separation, transduction with a lentiviral vector encoding the CAR, expansion, and final formulation within a single, sterile instrument. This automated approach minimizes manual handling, reduces the risk of contamination, and enhances the consistency of the final product.

The manufacturing process has proven to be highly efficient and reliable, with a 100% success rate reported in early cohorts.[17] The median time required for manufacturing the CAR-T cell product is just

6 days (range, 5-11).[17] This speed contributes to a highly competitive median

vein-to-vein time—the total duration from leukapheresis to product infusion—of only 19 days (range, 12-67).[17] This rapid turnaround is a significant operational and clinical advantage. Patients with aggressive, rapidly progressing lymphomas are at high risk of clinical deterioration during the manufacturing period. A shorter vein-to-vein time minimizes this "waiting period," reducing the need for bridging therapies and increasing the likelihood that a patient will remain eligible to receive the potentially curative infusion. This logistical efficiency is a key differentiator that can improve patient outcomes and enhance the therapy's attractiveness to clinicians and healthcare systems.

Deep-Dive Analysis of Clinical Efficacy

The clinical efficacy of prizloncabtagene autoleucel has been consistently and impressively demonstrated across multiple data readouts with progressively longer follow-up. The results show not only exceptionally high initial response rates but, more importantly, a remarkable durability of these responses over several years.

Response Rates: A Longitudinal Review of ORR and CR Data

The consistency of the top-line efficacy results is a key strength of the C-CAR039 clinical program. As the patient cohort expanded and the follow-up duration increased, the overall and complete response rates have remained remarkably stable, indicating that the early, promising signals were robust and not subject to significant decay over time.

• Early Data (ASCO 2021): Initial results from an efficacy-evaluable set of 27 patients with r/r B-NHL demonstrated an Overall Response Rate (ORR) of 92.6%, with an impressive Complete Response (CR) rate of 85.2%.[18]
• Updated Data (ASH 2023): With the cohort expanded to 48 infused patients (47 evaluable for efficacy) and a median follow-up of 30.0 months, the results remained exceptionally strong. The ORR was 91.5% and the CR rate was 85.1%.[3] The median time to first response was rapid at 1.0 month.[24]
• Long-Term Data (EHA 2025): Further follow-up on the same cohort of 48 patients, now with a median follow-up of 45.5 months, confirmed the stability of these responses. The ORR and CR rates were maintained at 91.5% and 85.1%, respectively.[12]
• Global Study Data (JNJ-90014496, EHA 2025): The first data from the global Phase 1b study corroborated these findings in a non-Chinese patient population. In the cohort of 22 patients treated at the recommended Phase 2 dose, the ORR was 100% for patients with one prior line of therapy and 92% for those with two or more prior lines. The corresponding CR rates were 80% and 75%, respectively.[7]

This longitudinal data provides high confidence in the therapy's ability to induce deep responses in a very high proportion of patients with heavily pre-treated B-NHL.

Data Readout (Conference, Year)	Patient Cohort (n)	Median Follow-up	Overall Response Rate (ORR)	Complete Response (CR) Rate	Source(s)
ASCO 2021	27	7 months	92.6%	85.2%	18
ASH 2023	47	30.0 months	91.5%	85.1%	3
EHA 2025	47	45.5 months	91.5%	85.1%	12
JNJ-90014496 (EHA 2025)	22 (RP2D)	4 months	92-100%	75-80%	7

Durability of Clinical Benefit: Long-Term Progression-Free and Overall Survival Outcomes

While high initial response rates are encouraging, the ultimate measure of success for a potentially curative therapy is the durability of those responses. In this regard, prizloncabtagene autoleucel has produced exceptional long-term data. In the 48-patient cohort from the AbelZeta study, with a median follow-up of 30.0 months, the median Duration of Response (DOR), median Progression-Free Survival (PFS), and median Overall Survival (OS) were all not reached, indicating that more than half of the patients remained alive, free of disease progression, and in response at the time of the analysis.[3]

Kaplan-Meier survival estimates provide a more detailed picture of this long-term benefit:

• At a median follow-up of 30.0 months, the estimated 24-month PFS rate was 62.6%, and the 24-month OS rate was 76.5%.[3]
• With extended follow-up to a median of 45.5 months, the estimated 48-month PFS rate was 52.5%, and the 48-month OS rate was 65.4%.[12]

These results are highly significant. They demonstrate that years after a single infusion of prizloncabtagene autoleucel, a majority of these patients with advanced, refractory lymphoma are still alive, and more than half remain free of disease progression. This level of durable disease control strongly supports the assertion that the therapy has "curative potential" for a substantial subset of patients.[27]

Efficacy Across B-NHL Subtypes and High-Risk Populations

The robust efficacy of prizloncabtagene autoleucel extends to the most common and clinically important subtype of B-NHL, Large B-Cell Lymphoma (LBCL). In the sub-analysis of 43 patients with LBCL (including DLBCL, tFL, and PMBCL), the efficacy was consistent with the overall population:

• ORR of 90.7% and a CR rate of 86.0%.[24]
• The long-term survival estimates were also strong, with a 48-month PFS rate of 53.4% and a 48-month OS rate of 66.7%.[27]

This demonstrates that the therapy is highly effective in patients with aggressive lymphomas, which constitute the largest area of unmet need and the primary commercial market for CAR-T therapies in B-NHL.

Pharmacokinetic Profile: In Vivo Expansion and Persistence Dynamics

The durable clinical efficacy of prizloncabtagene autoleucel is directly supported by its pharmacokinetic profile, which measures the behavior of the CAR-T cells in the patient's body after infusion. The therapy demonstrated robust and consistent expansion in vivo, reaching a peak concentration in the peripheral blood at a median of 11 to 11.5 days (Tmax) post-infusion.[1]

More importantly, the CAR-T cells exhibited long-term persistence, a characteristic feature of constructs utilizing the 4-1BB costimulatory domain. The median last timepoint at which the CAR-T cells were detectable in the blood (Tlast) was 216 days.[24] This prolonged persistence is the biological mechanism that enables ongoing immunosurveillance, allowing the engineered T-cells to control residual disease and prevent relapse over an extended period, thereby translating into the durable clinical responses and long-term survival observed in the trials.

Comprehensive Safety and Tolerability Assessment

A defining feature of prizloncabtagene autoleucel is its favorable and highly manageable safety profile. While on-target toxicities are expected with any effective CAR-T therapy, the incidence of severe, life-threatening adverse events with prizloncabtagene autoleucel has been remarkably low, positioning it as a potentially safer alternative to currently approved therapies.

Characterization of Cytokine Release Syndrome (CRS)

Cytokine Release Syndrome (CRS) is a systemic inflammatory response caused by the activation and proliferation of CAR-T cells. It is the most common toxicity associated with this class of therapy. In the 48-patient cohort from the AbelZeta study, CRS of any grade was observed in 93.8% of patients (45 out of 48).[3] However, the vast majority of these events were low-grade and manageable.

The most critical safety finding is the exceptionally low rate of severe CRS. Only one patient (2.1%) experienced Grade 3 CRS, and there were no cases of Grade 4 or 5 (fatal) CRS.[3] This finding was further reinforced by the initial data from the global JNJ-90014496 study, which reported

zero cases of Grade 3 or 4 CRS in the 25 patients in the RP2D safety cohort.[8]

The clinical course of CRS was also predictable. The median time to onset was 3 days (range, 1-12), with a median duration of 5 days (range, 2-78), and all events were reversible.[24] This predictable and low-severity profile suggests that patients can be managed effectively with standard supportive care, often without the need for intensive care unit (ICU) admission.

Incidence and Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is another significant potential toxicity of CAR-T therapy, which can manifest with a range of neurological symptoms. The safety profile of prizloncabtagene autoleucel is particularly distinguished by its very low incidence of ICANS.

In the 48-patient AbelZeta cohort, only three patients (6.3%) experienced ICANS of any grade. Critically, all cases were low-grade (two Grade 1 and one Grade 2), and no severe (Grade ≥3) ICANS was reported.[3] All neurotoxicity events were resolved.[24]

In the JNJ-90014496 study, two cases of ICANS were observed: one Grade 1 and one Grade 3.[7] It is important to note that the single Grade 3 event occurred in a patient with pre-existing central nervous system (CNS) lymphoma, which is a known significant risk factor for developing neurotoxicity.[7]

The combination of a low overall incidence and the near-absence of severe neurotoxicity is a major differentiating feature of prizloncabtagene autoleucel. The ability to avoid severe, life-threatening toxicities is a primary concern for clinicians when selecting a CAR-T therapy. The favorable safety profile of prizloncabtagene autoleucel could therefore be a key driver of its adoption. This safety advantage may enable broader clinical application, potentially allowing for treatment in community oncology centers rather than being restricted to specialized academic institutions. It may also facilitate outpatient administration for a larger proportion of patients, reducing the burden on healthcare resources and improving the patient experience.

Adverse Event	Incidence (Any Grade)	Incidence (Grade ≥3)	Notes	Source(s)
Cytokine Release Syndrome (CRS)	93.8%	2.1%	All events were reversible.	24
ICANS	6.3%	0%	All events were Grade 1 or 2 and resolved.	24
Prolonged Neutropenia (not resolved by Day 30)	N/A	54.2%	Common hematologic toxicity related to lymphodepletion.	24
Prolonged Thrombocytopenia (not resolved by Day 30)	N/A	20.8%	Common hematologic toxicity related to lymphodepletion.	24
Prolonged Anemia (not resolved by Day 30)	N/A	20.8%	Common hematologic toxicity related to lymphodepletion.	24
Infections	66.7%	25.0%	A known risk following lymphodepletion and in this patient population.	24

Hematologic Toxicities and Other Adverse Events of Note

As is common with CAR-T cell therapies that require lymphodepleting chemotherapy, the most frequent Grade ≥3 adverse events were hematologic. Prolonged cytopenias (not resolved by Day 30 post-infusion) included neutropenia (54.2%), anemia (20.8%), and thrombocytopenia (20.8%).[24] These are managed with supportive care, such as growth factor support and transfusions. Grade

≥3 infections were observed in 12 of 48 patients (25.0%), a known risk in this immunocompromised patient population.[24] Three patients developed a second primary malignancy after infusion, but none were considered by investigators to be related to the C-CAR039 therapy itself.[24]

Regulatory and Commercial Landscape

The promising clinical profile of prizloncabtagene autoleucel has been recognized by regulatory authorities and has attracted a major commercial partner, positioning the therapy for an expedited development path and a strong global launch.

Navigating the Regulatory Pathway: Analysis of FDA Designations

The U.S. Food and Drug Administration (FDA) has granted prizloncabtagene autoleucel several key designations that are intended to accelerate its development and review, signaling the agency's belief that it may offer a significant advantage over available therapies for a serious condition.

• Regenerative Medicine Advanced Therapy (RMAT) Designation: Granted for the treatment of r/r DLBCL, this is one of the FDA's most significant expedited program designations. It acknowledges that the therapy has preliminary clinical evidence indicating the potential to address unmet medical needs and provides the benefits of more intensive FDA guidance and eligibility for priority review.[10]
• Fast Track Designation: Also granted for r/r DLBCL, this designation is designed to facilitate the development and expedite the review process for drugs that treat serious conditions and fill an unmet medical need.[10]
• Orphan Drug Designation: Granted in June 2021 for the treatment of Follicular Lymphoma, this designation provides development incentives, including tax credits and market exclusivity, to encourage the development of therapies for rare diseases.[11]
• Investigational New Drug (IND) Clearance: The FDA cleared the IND application for C-CAR039 in December 2021, officially permitting the initiation of clinical trials in the United States.[10] Subsequently, the Centre for Drug Evaluation (CDE) in China also approved the IND application, allowing for formal clinical studies in that region.[13]

The AbelZeta-Janssen Strategic Alliance: Implications for Global Commercialization

A pivotal event in the development of prizloncabtagene autoleucel was the establishment of a global collaboration and license agreement between AbelZeta Pharma and Janssen Biotech, Inc. (a Johnson & Johnson company) in May 2023.[7] Under the terms of the agreement, Janssen acquired exclusive worldwide rights to develop and commercialize C-CAR039 (JNJ-90014496) and a related asset, C-CAR066, in all territories outside of Greater China. The deal involved a substantial

$245 million upfront payment to AbelZeta, with eligibility for additional development, regulatory, and commercial milestone payments, plus tiered royalties on net sales.[10]

In December 2023, the agreement was amended to provide Janssen with an option to secure exclusive commercialization rights in China as well, effectively consolidating the asset's global future under a single, powerful commercial entity.[13] This partnership is transformative, providing prizloncabtagene autoleucel with the extensive resources, clinical trial infrastructure, manufacturing scale, and commercial expertise of Johnson & Johnson, one of the world's largest pharmaceutical companies. This backing is critical for navigating the complex path to global regulatory approval and for competing effectively in the established CAR-T market.

Competitive Positioning Against Incumbent and Pipeline Therapies

Prizloncabtagene autoleucel is entering a market with several established competitors. The primary competitors are the currently approved anti-CD19 CAR-T therapies for various B-NHL indications:

• Axicabtagene ciloleucel (Axi-cel, brand name Yescarta®): Developed by Kite, a Gilead Company.
• Tisagenlecleucel (Tisa-cel, brand name Kymriah®): Developed by Novartis.
• Lisocabtagene maraleucel (Liso-cel, brand name Breyanzi®): Developed by Bristol Myers Squibb.
• Brexucabtagene autoleucel (Brexu-cel, brand name Tecartus®): Also from Kite/Gilead, approved specifically for r/r Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia. [22]

The competitive strategy for prizloncabtagene autoleucel will hinge on its ability to demonstrate superiority over these incumbents, primarily through its potentially better efficacy and durability (driven by the bispecific design) and its demonstrably more favorable safety profile (lower rates of severe CRS and ICANS).

Therapy (Brand Name)	Pivotal Trial	Target(s)	Costimulatory Domain	ORR (%)	CR (%)	Long-Term OS	Grade ≥3 CRS (%)	Grade ≥3 ICANS (%)
Prizloncabtagene autoleucel	Phase 1 (IIT)	CD19 / CD20	4-1BB	91.5%	85.1%	76.5% (2-yr)	2.1%	0%
Axi-cel (Yescarta®)	ZUMA-1	CD19	CD28	83%	58%	42.6% (5-yr)	13%	31%
Tisa-cel (Kymriah®)	JULIET	CD19	4-1BB	53%	40%	36% (3-yr, est.)	23%	12%
Liso-cel (Breyanzi®)	TRANSCEND	CD19	4-1BB	73%	53%	N/A	2%	10%
Note: Data are from respective pivotal trials and long-term follow-ups and may involve different patient populations and grading criteria, requiring cautious interpretation. ORR/CR for Tisa-cel are from 6-month analysis. Sources:.3

Synthesis, Strategic Insights, and Future Outlook

A comprehensive analysis of prizloncabtagene autoleucel reveals a therapeutic asset with a compelling, multi-faceted value proposition. By synthesizing the data on its molecular design, clinical performance, and strategic positioning, a clear picture emerges of a next-generation CAR-T therapy with the potential to redefine the standard of care for B-cell malignancies.

Comparative Assessment: Benchmarking C-CAR039 Against Approved CAR-T Therapies

When benchmarked against the pivotal trial data of approved anti-CD19 CAR-T therapies, prizloncabtagene autoleucel appears to demonstrate a superior profile in both efficacy and safety.

• Efficacy Comparison: The complete response rate of 85.1% observed with prizloncabtagene autoleucel in a heavily pre-treated r/r B-NHL population is substantially higher than the CR rates reported in the pivotal trials for axi-cel (58% in ZUMA-1), tisagenlecleucel (40% in JULIET), and lisocabtagene maraleucel (53% in TRANSCEND NHL 001).[24] While cross-trial comparisons must be made with caution, the magnitude of this difference is clinically significant and suggests a more profound anti-tumor activity. Furthermore, the long-term survival data, with a 48-month PFS rate of 52.5%, points toward a higher probability of durable, long-term remission compared to historical outcomes.[27]
• Safety Comparison: The safety advantage is arguably even more pronounced. The reported rate of severe (Grade ≥3) CRS with prizloncabtagene autoleucel is 2.1%, and the rate of severe (Grade ≥3) ICANS is 0% in the primary 48-patient cohort.[24] These figures compare very favorably to those for axi-cel (13% Grade ≥3 CRS, 31% Grade ≥3 ICANS) and tisagenlecleucel (23% Grade ≥3 CRS, 12% Grade ≥3 ICANS).[50] While lisocabtagene maraleucel also has a favorable CRS profile (2% Grade ≥3), its rate of severe ICANS (10%) is higher than that observed with prizloncabtagene autoleucel.[54] This superior safety profile could be a decisive factor in clinical decision-making.

Defining the "Best-in-Class" Potential: An Evidence-Based Perspective

The combination of these attributes forms a strong, evidence-based argument for prizloncabtagene autoleucel's potential to become a "best-in-class" CAR-T therapy for B-NHL. This assertion is built upon three interconnected pillars:

1. Superior Molecular Design: The synergistic architecture combining bispecific CD19/CD20 targeting to overcome antigen escape with a 4-1BB costimulatory domain to ensure long-term persistence directly addresses the key biological challenges that limit the success of first-generation therapies.
2. Superior and More Durable Efficacy: The clinical data consistently show higher rates of deep, complete responses and robust long-term progression-free and overall survival rates, suggesting a greater potential for curative outcomes.
3. Superior Safety Profile: The markedly lower incidence of severe CRS and ICANS offers a significant clinical advantage, potentially reducing patient morbidity, lowering the intensity and cost of care, and expanding eligibility to a broader patient population.

Unmet Needs and Future Directions for Clinical Investigation

With its strong profile in the relapsed/refractory setting established, the future development of prizloncabtagene autoleucel will likely focus on addressing further unmet needs. A key strategic direction will be to move the therapy into earlier lines of treatment. Based on the success of axi-cel and liso-cel in pivotal trials that moved CAR-T therapy into the second-line setting for LBCL patients who relapse early or are refractory to first-line chemoimmunotherapy, a similar path for prizloncabtagene autoleucel is a logical next step.[23] Given its potentially superior efficacy and safety, it could prove to be a highly competitive option in this setting, challenging the long-standing standard of care involving salvage chemotherapy and autologous stem cell transplantation. Further investigation may also explore its utility in other B-cell malignancies or in patient populations with specific high-risk features.

Concluding Analysis and Strategic Recommendations

In conclusion, prizloncabtagene autoleucel (C-CAR039 / JNJ-90014496) is a highly promising, next-generation CAR-T therapy that has demonstrated a compelling and consistent profile of high, durable efficacy and favorable safety in patients with relapsed/refractory B-cell Non-Hodgkin's Lymphoma. Its intelligent molecular design appears to have successfully translated into superior clinical outcomes compared to historical data for approved therapies. The asset is significantly de-risked through extensive clinical validation and is now poised for global late-stage development and commercialization under the stewardship of Johnson & Johnson. Based on the totality of the available evidence, prizloncabtagene autoleucel has a clear potential to become a new standard of care, offering a more effective and safer treatment option with curative potential for a significant number of patients with these challenging hematologic malignancies.

Works cited

1. Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). | Request PDF - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/352072829_Safety_and_efficacy_of_a_novel_anti-CD20CD19_bi-specific_CAR_T-cell_therapy_C-CAR039_in_relapsed_or_refractory_rr_B-cell_non-Hodgkin_lymphoma_B-NHL
2. Prizloncabtagene autoleucel - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 29, 2025, https://synapse.patsnap.com/drug/57c237aceec5417fa0fbe42f09c20519
3. A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/39813680/
4. Prizloncabtagene autoleucel: Uses, Interactions, Mechanism of ..., accessed September 29, 2025, https://go.drugbank.com/drugs/DB18623
5. C-CAR039, A NOVEL ANTI-CD20/CD19 BI-SPECIFIC CAR T-CELL THERAPY... - Liang A - - Jun 13 2024 - EHA Library, accessed September 29, 2025, https://library.ehaweb.org/eha/2024/eha2024-congress/419562/aibin.liang.c-car039.a.novel.anti-cd20.cd19.bi-specific.car.t-cell.therapy.html
6. NCT05149391 | A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT05149391
7. Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma, accessed September 29, 2025, https://innovativemedicine.jnj.com/us/news-center/oncology/johnson-johnsons-dual-targeting-car-t-cell-therapy-shows-encouraging-first-results-in-large-b-cell-lymphoma
8. Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma, accessed September 29, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnsons-dual-targeting-car-t-cell-therapy-shows-encouraging-first-results-in-large-b-cell-lymphoma
9. Prizloncabtagene autoleucel - AbelZeta Pharma - AdisInsight - Springer, accessed September 29, 2025, https://adisinsight.springer.com/drugs/800056981
10. Cellular Biomedicine Group Announces Exclusive Collaboration and License Agreement with Janssen to Develop and Commercialize anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma - PR Newswire, accessed September 29, 2025, https://www.prnewswire.com/news-releases/cellular-biomedicine-group-announces-exclusive-collaboration-and-license-agreement-with-janssen-to-develop-and-commercialize-anti-cd19--cd20-bi-specific-and-anti-cd20-car-ts-for-non-hodgkin-lymphoma-301812963.html
11. CBMG Holdings' Novel CD19/CD20 Bi-specific CAR-T Cell Product Shows Early Promising Clinical Efficacy and Favorable Safety Profile in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - BioSpace, accessed September 29, 2025, https://www.biospace.com/cbmg-holdings-novel-cd19-cd20-bi-specific-car-t-cell-product-shows-early-promising-clinical-efficacy-and-favorable-safety-profile-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma
12. AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025 - PR Newswire, accessed September 29, 2025, https://www.prnewswire.com/news-releases/abelzeta-announces-promising-long-term-outcomes-for-c-car039-a-novel-cd19cd20-bi-specific-car-t-therapy-in-patients-with-rr-b-nhl-at-eha-2025-302482119.html
13. AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China, accessed September 29, 2025, https://www.abelzeta.com/abelzeta-announces-amendment-to-worldwide-collaboration-and-license-agreement-with-janssen-to-include-china/
14. AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/RB NHL at EHA 2025, accessed September 29, 2025, https://www.abelzeta.com/embed/
15. AbelZeta Presents Data from Two Clinical Studies Relating to its Immuno-Oncology Drug Development at the 65th ASH Annual Meeting, accessed September 29, 2025, https://www.abelzeta.com/abelzeta-presents-data-from-two-clinical-studies-relating-to-its-immuno-oncology-drug-development-at-the-65th-ash-annual-meeting/
16. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies, accessed September 29, 2025, https://www.jnj.com/media-center/press-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-cellular-biomedicine-group-to-develop-next-generation-car-t-therapies
17. Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/346662386_Developing_a_Novel_Anti-CD19CD20_Bi-Specific_Chimeric_Antigen_Receptor_T_CAR-T_Cell_Therapy_for_RelapsedRefractory_rr_B-Cell_NHL
18. C-CAR039 Demonstrates Promising Efficacy, Safety in Relapsed/Refractory B-NHL, accessed September 29, 2025, https://www.onclive.com/view/promising-results-yielded-by-car-t-cell-therapy-c-car039-in-relapsed-refractory-b-cell-nhl
19. Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). - ASCO, accessed September 29, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT339807
20. KYMRIAH® (tisagenlecleucel) Mechanism of Action for DLBCL, accessed September 29, 2025, https://www.kymriah-hcp.com/diffuse-large-b-cell-lymphoma-adults/mechanism-of-action
21. The Mechanism of Action of CAR T - YouTube, accessed September 29, 2025, https://www.youtube.com/watch?v=l59Ij__ln3c
22. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences - PMC - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7326110/
23. CAR T-Cell Advances in Lymphoma: Implications for Managed Care | AJMC, accessed September 29, 2025, https://www.ajmc.com/view/car-t-cell-advances-in-lymphoma-implications-for-managed-care
24. c-car039, a novel anti-cd20/cd19 bi-specific car t-cell therapy shows deep - EHA Library, accessed September 29, 2025, https://library.ehaweb.org/eha/2024/eha2024-congress/document?c_id=419562&cm_id=434395&type=document434395
25. Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10898044/
26. Comparison of efficacy and adverse effects of CD19/20 CART ..., accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12089104/
27. AbelZeta Announces Promising Long-Term Outcomes for C ..., accessed September 29, 2025, https://www.abelzeta.com/abelzeta-announces-promising-long-term-outcomes-for-c-car039-a-novel-cd19-cd20-bi-specific-car-t-therapy-in-patients-with-r-r-b-nhl-at-eha-2025/
28. Agonism of 4-1BB for immune therapy: a perspective on ... - Frontiers, accessed September 29, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1228486/full
29. The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies | bioRxiv, accessed September 29, 2025, https://www.biorxiv.org/content/10.1101/2025.02.28.640707v1.full-text
30. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma - IRIS Unina, accessed September 29, 2025, https://www.iris.unina.it/retrieve/handle/11588/810416/343775/CAR%20GD2.pdf
31. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6694/15/10/2767
32. C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up | Blood | American Society of Hematology, accessed September 29, 2025, https://ashpublications.org/blood/article/142/Supplement%201/1025/501613/C-CAR039-a-Novel-Anti-CD20-CD19-Bi-Specific-CAR-T
33. Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). - ASCO Publications, accessed September 29, 2025, https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.2507
34. FDA Grants RMAT/Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCL, accessed September 29, 2025, https://www.onclive.com/view/fda-grants-rmat-fast-track-designations-to-c-car039-for-relapsed-refractory-dlbcl
35. A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma | Request PDF - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/388040250_A_phase_1_trial_of_prizloncabtagene_autoleucel_a_CD19CD20_CAR_T-cell_therapy_for_relapsedrefractory_B-cell_non-Hodgkin_lymphoma
36. Study Details | NCT04655677 | A Study of C-CAR039 Treatment in ..., accessed September 29, 2025, https://clinicaltrials.gov/study/NCT04655677
37. Study Details | NCT04693676 | A Study of C-CAR039 Treatment in ..., accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT04693676?term=AREA%5BConditionSearch%5D(%22B-cell%20Lymphoma%22)&rank=2
38. A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects - larvol clin, accessed September 29, 2025, https://clin.larvol.com/trial-detail/NCT04317885
39. NCT04696432 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT04696432
40. Study Details | NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT05418088
41. FDA Grants Fast Track Designation to C-CAR039 for DLBCL | Targeted Oncology, accessed September 29, 2025, https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-c-car039-for-dlbcl
42. CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - BioSpace, accessed September 29, 2025, https://www.biospace.com/cbmg-receives-fda-regenerative-medicine-advanced-therapy-and-fast-track-designations-for-bi-specific-anti-cd19-cd20-car-t-cell-therapy-for-relapsed-refractory-b-cell-non-hodgkin-lymphoma
43. Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11027517/
44. FDA Grants Regenerative Medicine Advanced Therapy and Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCL - CancerNetwork, accessed September 29, 2025, https://www.cancernetwork.com/view/fda-grants-regenerative-medicine-advanced-therapy-and-fast-track-designations-to-c-car039-for-relapsed-refractory-dlbcl
45. CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - PR Newswire, accessed September 29, 2025, https://www.prnewswire.com/news-releases/cbmg-receives-fda-clearance-of-ind-application-for-bi-specific-anti-cd19cd20-car-t-cell-therapy-for-relapsedrefractory-b-cell-non-hodgkin-lymphoma-301443153.html
46. AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China - PR Newswire, accessed September 29, 2025, https://www.prnewswire.com/news-releases/abelzeta-announces-amendment-to-worldwide-collaboration-and-license-agreement-with-janssen-to-include-china-302015262.html
47. Cellular Biomedicine draws a line under its past | ApexOnco - Oncology Pipeline, accessed September 29, 2025, https://www.oncologypipeline.com/apexonco/cellular-biomedicine-draws-line-under-its-past
48. Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non-Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network, accessed September 29, 2025, https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21938
49. New Settings of CAR-T Cell Therapy for Lymphoma | Encyclopedia MDPI, accessed September 29, 2025, https://encyclopedia.pub/entry/history/compare_revision/120839
50. Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma 5 ..., accessed September 29, 2025, https://ascopost.com/issues/march-25-2023/axicabtagene-ciloleucel-in-refractory-large-b-cell-lymphoma-5-year-results-of-the-zuma-1-trial/
51. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma - American Society of Hematology, accessed September 29, 2025, https://ashpublications.org/blood/article/141/19/2307/494672/Five-year-follow-up-of-ZUMA-1-supports-the
52. Primary analysis results from Novartis pivotal JULIET trial show ..., accessed September 29, 2025, https://www.novartis.com/us-en/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult-treat-cancer
53. Efficacy Data | KYMRIAH® (tisagenlecleucel) for DLBCL | HCP, accessed September 29, 2025, https://www.kymriah-hcp.com/diffuse-large-b-cell-lymphoma-adults/efficacy
54. Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with ..., accessed September 29, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT266537